FB Pixel no scriptInnovent expands portfolio, lifts H1 profit
MENU
KrASIA
Aug
28

Innovent expands portfolio, lifts H1 profit

just now
Innovent Biologics
Innovent Biologics reported H1 2025 revenue of RMB 5.95 billion, up 50.6% YoY, and net profit of RMB 1.21 billion. The company expanded its portfolio to 16 drugs, including three new oncology launches, advanced global pipeline trials, and reaffirmed its target of RMB 20 billion product revenue by 2027.
Share

Latest Pulses

See All

Most Recent